Creating a bank of blood cells to help patients after radiation exposure
Official title: Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury
Funded at Ossium Health, INC. · NIH-11006882 · Data updated 2026-11-12
This study is looking at how to create special blood cells from donated bone marrow to help people who have low blood cell counts after radiation exposure, with the goal of improving their chances of recovery while waiting for more permanent treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ossium Health, INC. NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 14, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $375,113 |
| NIH project number | 1R44AI183961-01A1 |
| Project ID | NIH-11006882 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced radiation exposure leading to severe blood cell deficiencies.
✕Less likely to help
Patients who have not been exposed to radiation or who have other underlying conditions unrelated to radiation injury may not benefit from this research.
What this research studies
This research focuses on developing a bank of myeloid progenitor cells from deceased donor bone marrow to provide a bridging therapy for patients suffering from transient pancytopenia due to radiation exposure. The approach involves using a specialized device to select specific blood cells based on certain markers, ensuring high purity. The effectiveness of these cells will be tested in laboratory models to assess their ability to improve survival rates in patients affected by acute radiation syndrome. This innovative method aims to offer immediate support to patients until more definitive treatments can be determined.
Why it matters
Potential benefit: If successful, this research could provide a critical therapy to enhance recovery and survival for patients exposed to harmful levels of radiation.
How similar studies have gone: Previous research has shown success in similar approaches, particularly in the selection and application of myeloid progenitor cells for treating blood disorders.
Where this research is happening
-
Ossium Health, INC.
San Francisco, United States Active
Researchers
- Principal investigator: Johnstone, Brian H. — Ossium Health, INC.
- Study coordinator: Johnstone, Brian H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.